HPLC + MS
Independently tested for identity and purity
NP-TIRZ-001
Apr 16, 2026
99.85%
View Certificate of Analysis
CAS# 2023788-19-2
Also Known As LY3298176
Class Synthetic Peptide
Form Lyophilized Powder
Receptor Target
Receptor Target
Tirzepatide (LY3298176, CAS# 2023788-19-2) is a synthetic peptide compound classified as a dual receptor agonist with binding activity at the GLP-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). Supplied by NexPept as a lyophilized powder for in vitro laboratory research use. This compound has not been authorized by Health Canada for any therapeutic, clinical, or human use.
Molecular Profile
CAS#, formula, molecular weight, analytical data
CAS#, formula, molecular weight, analytical data
| Property | Value |
|---|---|
| CAS Number | 2023788-19-2 |
| Research Designation | LY3298176 |
| Compound Class | Synthetic incretin-based peptide — dual receptor agonist |
| Receptor Targets | GLP-1R, GIPR |
| Physical Form | Lyophilized powder |
| Analytical Method | High-Performance Liquid Chromatography (HPLC) + Mass Spectrometry (MS) |
| Appearance | White to off-white lyophilized solid |
In Vitro Research Context
Receptor pharmacology — laboratory use only
Receptor pharmacology — laboratory use only
Glucagon-like peptide-1 receptor — incretin signalling pathway
Glucose-dependent insulinotropic polypeptide receptor
Tirzepatide is studied in preclinical in vitro settings as a pharmacological tool for investigating simultaneous dual-receptor agonism across the incretin signalling system. Research applications include receptor binding assays, competitive displacement studies, and in vitro signalling cascade analysis. As an investigational compound with defined receptor selectivity at GLP-1R and GIPR, it is used in controlled laboratory environments to study receptor pharmacology and downstream signalling mechanisms.
Research context: Tirzepatide is an investigational compound studied in scientific research involving GLP-1R and GIPR signalling pathways. It has not been authorized by Health Canada for human or veterinary use.
Available Formats
20mg · 50mg — lyophilized powder
20mg · 50mg — lyophilized powder
| Format | Net Quantity | Physical Form |
|---|---|---|
| Tirzepatide 20mg | 20 mg / vial | Lyophilized powder |
| Tirzepatide 50mg | 50 mg / vial | Lyophilized powder |
All formats are sourced from the same verified batch. Selection should be based on the quantity required for your specific in vitro research protocol as determined by qualified research personnel.
Laboratory Storage
Controlled storage conditions for lyophilized material
Controlled storage conditions for lyophilized material
Store sealed lyophilized material under controlled laboratory conditions in accordance with validated institutional SOPs and applicable technical documentation. Protect from light and moisture. Handling conditions should be established by qualified research personnel in accordance with the specific experimental protocol.
Note: No preparation, reconstitution, or administration instructions are provided. This compound is supplied for in vitro laboratory research use only. All handling must be conducted by qualified personnel following institutional safety protocols.
Research Literature
Scientific references & related resources
Scientific references & related resources
PubMed — LY3298176 / Tirzepatide — peer-reviewed scientific literature on this compound
Tirzepatide Research Peptide Overview — NexPept compound overview and in vitro research context
Research Peptides in Canada — sourcing and research context for Canadian laboratories
What Are Research Peptides? — peptide classification and in vitro research context
This product is supplied exclusively for in vitro laboratory and non-clinical research use by qualified research personnel. It is not authorized by Health Canada for human or veterinary use. No therapeutic, clinical, or health claims are made.
This material must not be administered to humans or animals. No dosage, preparation, reconstitution, or administration instructions are provided or implied. All handling and use must be conducted by qualified personnel in accordance with applicable institutional policies and legal requirements.
Be the first to review “Tirzepatide 50 mg”
Related products
Reviews
There are no reviews yet.